Physician profile
Nyan Win
NPI 1134187529
$928.73
in general payments reported to CMS, 2019-2025
25 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $68.27 · 2021: $49.99 · 2022: $40.21 · 2023: $91.08 · 2024: $123 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $166.45 | 2021-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $81.79 | 2019-2020 | |
| Novo Nordisk INC | $72.93 | 2019-2025 | Wegovy |
| Glaxosmithkline, LLC. | $69.98 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $49.04 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $46.53 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.62 | 2019 | |
| Amgen INC. | $37.03 | 2019-2024 | Repatha |
| Esperion Therapeutics, INC. | $32.78 | 2021-2023 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $31.14 | 2019 | |
| Xeris Pharmaceuticals, INC. | $29.78 | 2024 | Gvoke Hypopen |
| Lilly USA, LLC | $27.10 | 2019-2020 | |
| Dexcom, INC. | $26.93 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.21 | 2019-2021 | |
| Amarin Pharma, INC. | $24.42 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.18 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $22.93 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.20 | 2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $15.91 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.90 | 2019 | |
| Shire North American Group INC | $13.90 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.59 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.37 | 2019 | |
| Allergan, INC. | $12.02 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $10.00 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nyan Win listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.